AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35960896
Drug: Gefitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib plus chemotherapy (GCP: gefitinib 250 mg orally once daily combined with carboplatin plus pemetrexed in a 3-week cycle for six cycles followed by concurrent gefitinib and pemetrexed maintenance)
Trial: 35960896
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg orally, once daily)
Trial: 35960896
Drug: Gefitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib plus chemotherapy (GCP)
Trial: 33793273
Drug: All enrolled
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All enrolled parents (treatment and control)
Trial: 32811749
Drug: Integrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative medicine visits
Trial: 32786325
Drug: Sparse measurements
RxNorm normalized name: sparsentan
DrugBank: Sparsentan (DB12548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparse measurements of library molecules using a machine learning algorithm to predict molecular function.
Trial: 32216594
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice (pH = 3.5) with Phenobarbital (2.5 mg/kg)
Trial: 32216594
Drug: Mineral water
RxNorm normalized name: mineral water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral water (neutral pH) with Phenobarbital (2.5 mg/kg)
Trial: 35458200
Drug: High-dose kawakawa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose kawakawa tea (4 g/250 mL water)
Trial: 34882729
Drug: Medicine ball
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine ball throws protocol (3 sets of 6 repetitions using a 2 kg ball, throwing at maximal speed)
Trial: 34360184
Drug: G% (1RM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G% (1RM test group)
Trial: 35945770
Drug: Supervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised physical therapy exercise program plus 20 minutes PBMT (650 nm, 5 mW, 1 cm², 6 Joules, 3 sessions/week for 8 weeks) plus traditional medical treatment
Trial: 35945770
Drug: PBMT (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMT (same protocol as Group A, 3 sessions/week for 8 weeks) plus traditional medical treatment
Trial: 35276223
Drug: Adalimumab monotherapy
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab monotherapy (ADL)
Trial: 34727741
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis alone
Trial: 34428930
Drug: Control (Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Intravenous thrombolysis alone)
Trial: 33305723
Drug: Posaconazole injection
RxNorm normalized name: posaconazole Injection
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole injection 100 mg
Trial: 33305723
Drug: Posaconazole injection
RxNorm normalized name: posaconazole Injection
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole injection 200 mg
Trial: 33305723
Drug: Posaconazole injection
RxNorm normalized name: posaconazole Injection
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole injection 300 mg
Trial: 616118370
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection (control)
Trial: 33629803
Drug: Autoregulated heavy
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autoregulated heavy slow resistance training (HSRT) combined with extracorporeal shockwave therapy (ESWT)
Trial: 36192126
Drug: Short-course outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course outpatient antibiotic therapy
Trial: 36192126
Drug: Standard-course outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-course outpatient antibiotic therapy
Trial: 34014695
Drug: Tele.TAnDem (telephone-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele.TAnDem (telephone-based cognitive-behavioral therapy) consisting of 12 sessions over 6 months
Trial: 36821354
Drug: Avelumab 10
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 10 mg/kg every 2 weeks
Trial: 35856817
Drug: Oral Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Methotrexate 7.5 mg weekly for a maximum of 12 weeks
Trial: 35856817
Drug: Oral Mini
RxNorm normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Mini Pulse Betamethasone 3 mg weekly for a maximum of 12 weeks
Trial: 35921241
Drug: Structured exercise
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured exercise programme consisting of close kinetic chain (CKC) exercises 2 days a week for 12 weeks, in addition to prophylactic treatment.
Trial: 35921241
Drug: Conventional Treatment
RxNorm normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Treatment Group (CTG) received exercise training as described in the published literature.
Trial: 35921241
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (CG) continued to receive prophylactic treatment during the study period.
Trial: 32266380
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of aspirin twice daily
Trial: 32266380
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of aspirin thrice daily
Trial: 35665724
Drug: Integrative Korean
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Korean medicine treatment (IMKT) + Non-resistance manual therapy (NRT)
Trial: 35665724
Drug: Integrative Korean
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Korean medicine treatment (IMKT)
Trial: 35537105
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy as per protocol
Trial: 34524157
Drug: Phenylephrine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (50 μg)
Trial: 34524157
Drug: Norepinephrine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (4 μg)
Trial: 36105122
Drug: BCAA+FO supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA+FO supplement group (n=10)
Trial: 33619708
Drug: Postoperative oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative oxycodone combined with nonopioid analgesics
Trial: 32555990
Drug: Intrathyroid injection
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathyroid injection of dexamethasone (IID)
Trial: 34664816
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg, twice a day
Trial: 32924685
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg bolus before induction and 3 µg/kg/min infusion during surgery)
Trial: 32924685
Drug: Saline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.5 mg/kg bolus before induction and 3 µg/kg/min infusion during surgery)
Trial: 33860177
Drug: Psilocybin (20‐30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (20‐30 mg/70 kg) with overtone-based music
Trial: 33860177
Drug: Psilocybin (20‐30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (20‐30 mg/70 kg) with Western classical music
Trial: 33860177
Drug: Psilocybin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (30 mg/70 kg) with chosen music (overtone-based or Western classical)
Trial: 32022647
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) and Psychodynamic Therapy (PDT)
Trial: 32826769
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% twice-daily
Trial: 32680548
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein supplementation (30 g/day) with hypocaloric diet
Trial: 33620419
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo or no treatment not specified)
Trial: 35899977
Drug: Apomorphine sublingual
RxNorm normalized name: apomorphine Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine sublingual film (SL‐APO)
Trial: 35899977
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg, positive control)
Trial: 35816069
Drug: Nutraceutical supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical supplement
Trial: 35816069
Drug: Nutraceutical supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical supplement (after transitioning from placebo)
Trial: 33067310
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 2 mg/kg (maximum 40 mg), once daily for 3 days
Trial: 34622597
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose - Deep Learning (LD-DL)
Trial: 34622597
Drug: Normal Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Dose - Iterative Reconstruction (ND-IR)
Trial: 34622597
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose - Filtered Back Projection (LD-FBP)
Trial: 34622597
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose - Iterative Reconstruction (LD-IR)
Trial: 36122260
Drug: Ultrasound-guided bilateral
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided bilateral retrolaminar block with 20 mL of 0.25% bupivacaine and 5 µg/mL adrenaline (1:200000)
Trial: 36122260
Drug: Ultrasound-guided thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided thoracic epidural analgesia with 20 mL of 0.25% bupivacaine and 5 µg/mL adrenaline (1:200000)
Trial: 33382189
Drug: HBsAg-positive with
RxNorm normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg-positive with high HBV DNA (≥2000 IU/ml)
Trial: 34773923
Drug: GSK3358699 (1-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3358699 (1-40 mg)
Trial: 34773923
Drug: GSK3358699 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3358699 (10 mg)
Trial: 34773923
Drug: GSK3358699 (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3358699 (20-40 mg)
Trial: 34773923
Drug: GSK3358699 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3358699 (40 mg)
Trial: 32703316
Drug: medication alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medication alone
Trial: 33752148
Drug: Single-dose carbohydrates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose carbohydrates (administered 2–3 h before surgery)
Trial: 33752148
Drug: Double-dose carbohydrates
RxNorm normalized name: CARBOHYDRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose carbohydrates (administered 10 h before surgery and 2–3 h before surgery)
Trial: 33752148
Drug: Single-dose carbohydrates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose carbohydrates
Trial: 33752148
Drug: Double-dose carbohydrates
RxNorm normalized name: CARBOHYDRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose carbohydrates
Trial: 32859978
Drug: DEGs associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEGs associated with thioredoxin system and iron ion metabolism
Trial: 32859978
Drug: DEGs associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEGs associated with two-component system and pyruvate metabolism
Trial: 34355328
Drug: High pollution
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High pollution area (PM10: 121.44±43.49 μg/m3, PM2.5: 84.18±31.32 μg/m3)
Trial: 34355328
Drug: Moderate pollution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate pollution area (PM10: 89.7±37.34 μg/m3, PM2.5: 58±23.94 μg/m3)
Trial: 34355328
Drug: Low pollution
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low pollution area (PM10: 59.14±25.24 μg/m3, PM2.5: 38.97±16.87 μg/m3)
Trial: 34522871
Drug: L-arginine 1.66
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine 1.66 g twice a day
Trial: 35606250
Drug: Nutraceutical preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical preparation containing 3.75mg of monacolin K, 515mg of berberine and 50mg of coenzyme Q10 per tablet (Lipok®)
Trial: 32537828
Drug: MG impairment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG impairment index
Trial: 33177727
Drug: Natural delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural delivery without analgesic measures
Trial: 33917922
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy (APT)
Trial: 34850238
Drug: digital cognitive
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: digital cognitive behavior therapy for insomnia (dCBT‐I)
Trial: 36495861
Drug: Genomics-guided therapies,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genomics-guided therapies, standardized system for determining actionability of genomic alterations
Trial: 34814896
Drug: High Tone
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Tone Power Therapy
Trial: 34814896
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without High Tone Power Therapy)
Trial: 36335376
Drug: Proactive Outreach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive Outreach with Medication Opt‐out for Tobacco Treatment Engagement (PrOMOTE)
Trial: 35802618
Drug: Pre-operative hypnosis
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative hypnosis session and post-operative web-based Acceptance and Commitment Therapy (ACT)
Trial: 35802618
Drug: Pre-operative one-session
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative one-session mindfulness through an audio file and post-operative treatment as usual (TAU)
Trial: 35358441
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care plus rituximab (375 mg/m2 on days 3, 10, 17, and 24)
Trial: 32573396
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bright light therapy and fluoxetine
Trial: 33907251
Drug: Chloroquine 450
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine 450 mg BID on day 1 and 450 mg once daily from days 2 to 5 or Hydroxychloroquine 400 mg BID on day 1 and 400 mg once daily from days 2 to 5 (combined with standard care)
Trial: 33743063
Drug: Single preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative dose of 20-mg dexamethasone (Group B)
Trial: 33743063
Drug: Two perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two perioperative doses of 10-mg dexamethasone (Group C)
Trial: 33610726
Drug: French maritime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: French maritime pine bark extract (PBE) supplementation (50mg, two capsules/day for eight weeks)
Trial: 35570989
Drug: Dapagliflozin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin treatment
Trial: 33010148
Drug: No dapagliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No dapagliflozin treatment (Control)
Trial: 32106527
Drug: Liquid PEA
RxNorm normalized name: BOOST BREEZE LIQUID PEACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid PEA (167.5 mg Levagen+ with 832.5 mg maltodextrin)
Trial: 32106527
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo (1 g maltodextrin)
Trial: 34775865
Drug: 1% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% glucose isotonic electrolyte solution
Trial: 33350447
Drug: Rosuvastatin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin therapy for 48 weeks
Trial: 32725758
Drug: Behavioural Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural Activation (BA) treatment
Trial: 32624569
Drug: 150mg L-DOPA
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg L-DOPA
Trial: 38245818
Drug: Etrasimod 2
RxNorm normalized name: etrasimod 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrasimod 2 mg
Trial: 32344455
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg once daily for one week
Trial: 32962936
Drug: Sugammadex, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex, 4 mg/kg
Trial: 32877651
Drug: Trimetazidine 35
RxNorm normalized name: trimetazidine 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine 35 mg modified-release twice daily
Trial: 33761688
Drug: Qiming granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qiming granule combined with laser treatment
Trial: 33761688
Drug: Simple laser
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple laser treatment
Trial: 35259535
Drug: Dupilumab 200/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 200/300 mg
Trial: 34153006
Drug: Intrathecal 2‐chloroprocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 2‐chloroprocaine 3% 50 mg with fentanyl 15 µg
Trial: 34153006
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 0.75% 9 mg with fentanyl 15 µg
Trial: 34185138
Drug: Optimized dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized dose regimen based on BMI
Trial: 34217851
Drug: Long-interval dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Long-interval dinoprostone (3 mg vaginally 12 hours before OH)
Trial: 34217851
Drug: Short-interval dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Short-interval dinoprostone (3 mg vaginally 3 hours before OH)
Trial: 33465041
Drug: Serum albumin
RxNorm normalized name: Serum albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum albumin level < 3.5 mg/dL
Trial: 35050548
Drug: Valsartan oral
RxNorm normalized name: valsartan Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan oral solution 160 mg
Trial: 35050548
Drug: Valsartan suspension
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan suspension formulation
Trial: 35984425
Drug: Sitagliptin (DPP-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (DPP-4 inhibitor)
Trial: 32971991
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (250 mg tablet/day)
Trial: 34260297
Drug: NACRT (Neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NACRT (Neoadjuvant chemoradiotherapy) combined with postoperative adjuvant XELOX chemotherapy
Trial: 34260297
Drug: ACT (Postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT (Postoperative adjuvant chemotherapy with XELOX)
Trial: 32144924
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine basic treatments)
Trial: 35090175
Drug: Carrageenan gel
RxNorm normalized name: Carrageenan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrageenan gel
Trial: 35133871
Drug: Copanlisib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copanlisib (60 mg intravenous) once weekly on days 1, 8, and 15 in 28-day cycles until progression or toxicity
Trial: 32757247
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no ITR treatment)
Trial: 32026432
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with rituximab